“According to a new report published by Introspective Market Research, Cancer/Tumor Profiling Market by Technology, Cancer Type, and Application, The Global Cancer/Tumor Profiling Market Size Was Valued at USD 11.08 Billion in 2024 and is Projected to Reach USD 23.4 Billion by 2032, Growing at a CAGR of 9.8%.”

Cancer/Tumor Profiling refers to the comprehensive molecular examination of tumor tissue or liquid biopsy samples to detect specific genetic mutations, protein expressions, and other biomarkers. This advanced diagnostic process involves technologies like Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), and Immunohistochemistry (IHC) to create a detailed molecular signature of a patient's cancer. The information derived from this profiling is crucial for understanding tumor behavior, classifying the disease at the molecular level, and predicting its aggressiveness and likely response to various treatments.

The primary advantage of tumor profiling over traditional diagnostics lies in its ability to support Precision Oncologya modern approach that moves away from one-size-fits-all treatment by tailoring therapeutic strategies to an individual patient's unique genetic and molecular profile. This enables oncologists to select the most effective targeted therapies and immunotherapies, minimizing the use of ineffective treatments and reducing patient exposure to unnecessary side effects. Main uses are concentrated in clinical practice for diagnostics, prognosis, treatment selection, patient monitoring, and in the pharmaceutical industry for biomarker discovery and drug development.

Market Segmentation:

The Cancer/Tumor Profiling Market is segmented into Technology, Cancer Type, and Application. By Technology, the market is categorized into (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In-Situ Hybridization (ISH), Microarrays, and Others). By Cancer Type, the market is categorized into (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer, and Others). By Application, the market is categorized into (Personalized Medicine, Diagnostics, Biomarker Discovery, Prognostics, and Research).

Growth Driver:

The rising global incidence of cancer is the primary and most significant growth driver for the Cancer/Tumor Profiling Market. As the global population ages and exposure to various environmental and lifestyle risk factors increases, the number of new cancer cases continues to climb dramatically, with projections indicating a substantial rise in the overall cancer burden. This surge in prevalence necessitates increasingly accurate and comprehensive diagnostic tools to manage the disease effectively. Tumor profiling is indispensable as it provides the molecular data required for early detection, precise characterization, and the selection of optimal therapeutic regimens, directly addressing the critical demand created by the escalating cancer burden worldwide.

Market Opportunity:

A significant market opportunity lies in the burgeoning adoption of Liquid Biopsy techniques coupled with the integration of Artificial Intelligence (AI) and Big Data Analytics. Liquid biopsy offers a non-invasive alternative to traditional tissue biopsy, allowing for real-time monitoring of tumor evolution and treatment response using a simple blood draw. The vast, complex genomic and proteomic data generated by these advanced profiling methods can be effectively analyzed and interpreted using AI and machine learning algorithms. This integration dramatically enhances the precision and speed of diagnostics, leading to more accurate prognostic and predictive models, thereby accelerating the shift towards fully personalized and data-driven cancer care.

Detailed Segmentation:

The Cancer/Tumor Profiling Market is segmented on the basis of Technology, Cancer Type, and Application.

Technology

 The Technology segment is further classified into Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), and Immunohistochemistry (IHC), among others. Among these, the Next-Generation Sequencing (NGS) sub-segment accounted for the highest market share in 2024. NGS is dominant due to its capability for comprehensive genomic profiling, which enables the simultaneous identification of multiple genetic mutations, biomarkers, and treatment targets across various cancer types. Its high-throughput, speed, and cost-effectiveness in performing deep genomic analysis make it the preferred technology for large-scale cancer research, drug development, and the implementation of precision medicine protocols in modern oncology.

Cancer Type

 The Cancer Type segment is further classified into Breast Cancer, Lung Cancer, and Colorectal Cancer, among others. Among these, the Breast Cancer sub-segment accounted for the highest market share in 2024. This segment’s dominance is attributed to the high global prevalence of breast cancer, which is the most commonly diagnosed cancer worldwide. Furthermore, the established role of tumor profiling in managing breast cancerspecifically in identifying crucial biomarkers like HER2, estrogen receptor (ER), and progesterone receptor (PR) for targeted therapiesdrives the high adoption rate of these diagnostic services. The extensive research and development focused on breast cancer diagnostics and therapeutics further consolidate its leading position.

Some of The Leading/Active Market Players Are-

·         Illumina, Inc. (US)

·         F. Hoffmann-La Roche Ltd. (Switzerland)

·         QIAGEN N.V. (Germany)

·         Thermo Fisher Scientific Inc. (US)

·         NeoGenomics Laboratories, Inc. (US)

·         Guardant Health, Inc. (US)

·         Agilent Technologies, Inc. (US)

·         Sysmex Corporation (Japan)

·         PerkinElmer Inc. (US)

·         Exact Sciences Corporation (US)

·         Foundation Medicine, Inc. (US)

·         NanoString Technologies, Inc. (US)

·         Caris Life Sciences (US)

·         HTG Molecular Diagnostics, Inc. (US)

·         Abbott Laboratories (US)

...and other active players.

Key Industry Developments

Collaboration on Precision Oncology In April 2023, Agilent Technologies Inc. announced a collaboration with South Korea-based Theragen Bio to enhance its precision oncology methods using advanced bioinformatic solutions.

This partnership aims to combine Agilent’s expertise in cancer genomic profiling (CGP) and engineering with Theragen Bio’s software skills. The goal is to accelerate localized analysis capabilities and improve the speed and accuracy of treatment decisions for cancer patients in the Asia-Pacific region by leveraging superior data analysis and software integration.

Expansion of Genomic Testing in Asia-Pacific In July 2022, Guardant Health, a US-based precision oncology company, formed a strategic partnership with Adicon Holdings Limited, an independent clinical laboratory (ICL) company based in China.

This strategic alliance was formed to allow biopharmaceutical companies to efficiently conduct clinical trials in China. The collaboration provides access to Guardant Health's comprehensive genomic profiling (CGP) tests, which supports the increasing need for advanced molecular diagnostics in a rapidly expanding healthcare market.

Key Findings of the Study

·         Dominant Segments: The Next-Generation Sequencing (NGS) technology and the Breast Cancer segment maintain the highest market shares.

·         Leading Regions: North America currently dominates the market due to high R&D funding and advanced healthcare infrastructure.

·         Key Growth Drivers: The primary driver is the sharply increasing global incidence of cancer.

·         Market Trends: Significant trends include the growing adoption of liquid biopsy and the integration of AI/Big Data for analysis.

About Us

At Introspective Market Research Private Limited, we are a forward-thinking research consulting firm committed to driving growth in the Cancer/Tumor Profiling Market. With deep insights, strategic solutions, and holistic research, we empower businesses to achieve success and dominance in the global Cancer/Tumor Profiling industry.

More Info:- https://introspectivemarketresearch.com/reports/cancer-tumor-profiling-market/

📞 Contact Us

Introspective Market Research Pvt. Ltd.

 Phone: +91-91753-37569

 Email: sales@introspectivemarketresearch.com

Web: www.introspectivemarketresearch.com